SPDR FactSet Innovative Technology ETF (ARCA: XITK)

Dernières nouvelles pour SPDR FactSet Innovative Technology ETF (ARCA:XITK)

SPDR FactSet Innovative Technology ETF

Technology

Communication Services

Healthcare

Industrials

Other

Financial Services

Consumer Defensive

The index is designed to represent the performance of U.S.-listed stock and American Depository Receipts of Technology companies and Technology-related companies within the most innovative segments of the Technology sector and Electronic Media sub-sector of the Media sector, as defined by FactSet Research Systems, Inc. The fund generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index.

Super Micro Computer, Inc.

Nvidia Corp.

AppLovin Corp. Com Cl A

Impinj Inc

Daktronics Inc

Q2 Holdings, Inc.

Spotify Technology S.A.

Magnite Inc

Toast, Inc.

Camtek Ltd/israel

Fubotv, Inc.

Acm Research Inc

Hesai Group Adr

Doximity, Inc.

JFrog Ltd.

Udemy Inc

Check Point Software Technologies Ltd.

Genpact, Ltd.

Pinterest Inc. Class A

Okta Inc.

Concentrix Corporation

Paycor Hcm Inc

Clearwater Analytics Holdings Inc

Netflix, Inc.

Osi Systems Inc

Schrodinger Inc

Duolingo Inc

NVDA: 6% &#x7C; <a href="https://www.benzinga.com//node/45657660">Nvidia Q1 Highlights: China Export Ban Hits Results But Jensen Huang Says Demand ‘Incredibly Strong'</a>
&nbsp;
ELF: 8% &#x7C; <a href="https://www.benzinga.com//node/45659407">ELF stock has given up its prior loss. e.l.f. Beauty shares were trading lower following Q4 reported financial results.</a>
&nbsp;
ZEO: 147% &#x7C; <a href="https://www.benzinga.com//node/45664946">Zeo Energy to Acquire Heliogen in All-Stock Deal Valued at $10M</a>

Movers

Trading Ideas

NVDA

Market-Moving News for May 29th

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Intellia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) with a Buy and maintains $30 price target.

News

Price Target

Reiteration

Analyst Ratings

NTLA

HC Wainwright & Co. Reiterates Buy on Intellia Therapeutics, Maintains $30 Price Target

Earnings

Earnings Misses

DOOO

CORRECTION: BRP Q1 Adj. EPS $0.33 Beats $0.29 Estimate, Sales $1.30B Beat $1.23B Estimate

PLUG

Plug Power's Woodbine Plant Produces 300 Metric Tons Of Liquid Hydrogen In April 2025, Says It Set New US Record

Rosenblatt analyst Blair Abernethy maintains Synopsys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPS#NASDAQ">SNPS</a>) with a Buy and lowers the price target from $660 to $625.

SNPS

Rosenblatt Maintains Buy on Synopsys, Lowers Price Target to $625

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4437443-1&amp;h=2153320783&amp;u=http%3A%2F%2Fwww.imux.com%2F&amp;a=Immunic%2C+Inc.">Immunic, Inc.</a> ("Immunic" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMUX#NASDAQ">IMUX</a>), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the pricing of an underwritten public offering of (i) pre-funded warrants to purchase shares of common stock (the "Pre-Funded Warrants"), (ii) series A warrants to purchase shares of common stock (or pre-funded warrants) (the "Series A Warrants"), and (iii) series B warrants to purchase shares of common stock (or pre-funded warrants) (the "Series B Warrants"). The combined public offering price of one Pre-Funded Warrant, one Series A Warrant, and one Series B Warrant, which are being sold together but are immediately seperable, is $0.7499. The Pre-Funded Warrants will be immediately exercisable, and may be exercised at any time after their original issuance. The Series A Warrants will be immediately exercisable any time before December 31, 2025. The Series B Warrants will be exercisable beginning on October 1, 2025, or earlier if certain thresholds are met, until five years from the date of issuance. The Series A and B Warrants will immediately expire in proportion to the extent that the corresponding pre-funded warrant offered hereby is exercised on or prior to September 30, 2025, subject to certain exceptions.
All securities in the offering are being sold by Immunic.
The initial gross proceeds from the offering are expected to be approximately $65 million before deducting underwriting discounts and commissions and offering expenses. The Company may receive up to an aggregate of $130 million of additional gross proceeds if the Series A Warrants and Series B Warrants are exercised in full for cash. The offering is expected to close on or about June 3, 2025, subject to the satisfaction of customary closing conditions.
The Company intends to use the net proceeds received from the proposed offering to fund its clinical trials and operations and for other general corporate purposes.

Offerings

IMUX

Immunic Raises $65M in Public Offering, Could Gain $130M More From Warrant Exercises

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) with a Buy and maintains $72 price target.

HALO

HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $72 Price Target

<ul>
<li>Baker Hughes will supply 16 NovaLT&#x2122; gas turbines for data center projects in the U.S.</li>
<li>Award builds on the collaboration announced in March 2025 between Baker Hughes and Frontier</li>
</ul>
HOUSTON and LONDON, May 29, 2025 (GLOBE NEWSWIRE) -- Baker Hughes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>), an energy technology company, announced Wednesday an award from Frontier Infrastructure Holdings ("Frontier"), a Tailwater Capital LLC portfolio company, for 16 NovaLT&#x2122; gas turbines to power its data center projects in Wyoming and Texas, delivering up to 270 megawatts (MW) of efficient, reliable power.
As part of the award, Baker Hughes is supplying Frontier its <a href="https://www.globenewswire.com/Tracker?data=1LV8ChHFkk9Pa1krc62Q3c6TtVpM8K-vT-vj1ZT6BC7Vofyi0klMnkluCXqPpTWtjBAGhm62zO3HDD4-xzpvV4nozs9VZrvOk-dN1pDde4PZDI9B-l1E1UP26k5pvBX9YA6CqmkOvDqpWzaW8new9qN8v3WP7GK_egD2TETCDFQ=">NovaLT&#x2122; gas turbine technology</a> and associated equipment, including <a href="https://www.globenewswire.com/Tracker?data=IRtsZorW4PO-67Ov09E5ll1dWN7jvaIOoaOVQe3e2bogMOTecaiEZMVaoxXYFKz4ckdy76asn2sTtNbeoGrCSDdvpy78qsaDuSx8WuSIm16Brq4ytcAWhMkYLMTn7ulthpYTkV2ZrHYqzna4KADOYw==">gears</a> and <a href="https://www.globenewswire.com/Tracker?data=GFsT_NbBwlRrM50HfW1GG3Xs81mfCfcHmpsPna26exuD-h60RL6dRycBgpeinRThEfUavtZwWn-5JYuXQ73vcAJnoJXPXm0zYYYSp4oZhGLJCvbpKzxVrEwhAj2MSrM35zBzwpH9mgkMhXtg3-Uxylx_A6piu93Q7zzqPS1yE_M=">Brush Power Generation four-pole generators</a>, to power dedicated energy islands at Frontier's behind-the-meter (BTM) power generation sites.
The order builds on <a href="https://www.globenewswire.com/Tracker?data=PB9-TIH9Q4Iemu8H2RzLkjVQAIfylf9ScuQBhzkTsr6t5teUoaiftlMJHpcAZLh2tEzpH8ymVkvL8cGjfSKTKQi_bcpVHwg85qAo90ofb-8LnsV_vykXXO2ovYfT5tEiifyKPHnFeIIifXxJqu9VUgpXu-oyyhyfWvJ7cxYT_6L42pg2FTOte8aoi7w9zdte_Zyf0j6p7adkVygeNtX1pd0jla1BdVHkGTsdR9B_pNyWySD6jow6WTREc_Zt_mqDuT4olNL9Wmy6A2KtPzeZRw==">a March 2025 agreement between the two companies</a> to accelerate large-scale carbon capture and storage ("CCS") and power solutions in the U.S., including the Sweetwater Carbon Storage Hub in Wyoming.

Baker Hughes To Supply 16 NovaLT Gas Turbines For Data Center Projects In US

Rosenblatt analyst Kevin Cassidy maintains NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) with a Buy and raises the price target from $178 to $200.

Rosenblatt Maintains Buy on NVIDIA, Raises Price Target to $200

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintains Eton Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETON#NASDAQ">ETON</a>) with a Buy and raises the price target from $33 to $35.

ETON

HC Wainwright & Co. Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $35

Kohl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) affirms FY2025 GAAP EPS guidance from $0.10-$0.60 to $0.10-$0.60 vs $0.44 analyst estimate. Affirms FY2025 sales outlook from $14.31 billion-$14.62 billion to $14.31 billion-$14.62 billion vs $14.59 billion estimate.

Guidance

Kohl's Affirms FY2025 Sales Guidance of $14.31B-$14.62B vs $14.59B Est

Biotech

General

Biologics License Application For Daiichi Sankyo And Merck's Patritumab Deruxtecan Has Been Withdrawn Based On Topline Overall Survival (OS) Results From HERTHENA-Lung02  Trial Where OS Did Not Meet Statistical Significance

Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) steady rally to a new all-time high of $111,000 may soon face significant headwinds, according to new <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45384651/bitcoin-rally-is-in-a-high-risk-high-reward-zone-glassnode">on-chain data from Glassnode.</a>
What Happened: The analytics firm highlights $120,000 as a critical price level where historical trends suggest a sharp increase in sell-side pressure is likely to emerge.
The <a href="https://insights.glassnode.com/the-week-onchain-week-21-2025/">report</a> finds that investor profitability has risen sharply since the recent breakout, with on-chain models showing parallels to previous market tops. 
Key indicators such as unrealized profits, spending behavior and exchange inflows all suggest a growing willingness among investors to lock in gains, particularly as prices approach the upper bounds of historically overheated ranges.
Glassnode&#8217;s use of the MVRV Ratio and short-term holder cost-basis analysis reveals that the $119,000–$120,000 range is now closely aligned with thresholds that marked local tops in previous cycles. 
These bands have only been surpassed during 17.5% of Bitcoin's trading history, reinforcing the rarity and risk of the current pricing environment.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45651580/want-to-earn-yield-on-your-bitcoin-heres-how">Want To Earn Yield On Your Bitcoin? Here&#8217;s How</a>
Why It Matters: Despite <a href="https://www.benzinga.com/money/best-spot-bitcoin-etfs">strong ETF inflows</a> and rising open interest in derivatives markets, the report underscores caution.
While bullish momentum remains intact, the market is entering territory where profit-taking could accelerate and test the resilience of support levels.
Net realized profit/loss metrics further confirm that profit margins on coins being sold are unusually high, with the average realized profit around $9,300 per coin.
Simultaneously, centralized exchange activity has spiked, with about 33% of all on-chain volume now routed through trading platforms, marking a clear uptick in speculation and distribution.
Glassnode warns that while current activity reflects a healthy bull market phase, the clustering of technical and on-chain resistance levels near $120,000 increases the likelihood of a local price correction.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45646680/trump-familys-expanding-crypto-ties-raise-questions-on-ethics-influence-and-investor-risk">Trump Family&#8217;s Expanding Crypto Ties Raise Questions On Ethics, Influence, And Investor Risk</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin Faces Potential Sell-Off Near $120,000 As Profit-Taking Rises, Glassnode Warns

Kohl's Corporation Q1 Comparable Sales Down 3.9%

WIIM

Kohl's shares are trading higher following better-than-expected Q1 financial results.

Immunovant (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMVT#NASDAQ">IMVT</a>) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.73) by 12.33 percent. This is a 23.08 percent decrease over losses of $(0.52) per share from the same period last year.

Earnings Beats

IMVT

Immunovant Q4 EPS $(0.64) Beats $(0.73) Estimate

Events

LTRX

Lantronix To Do Demos Of Its LM4 AI-driven Out-of-Band Management Platform At Cisco Lice Jun. 9-12

FRHC

Freedom Holding To Join Russell 3000 On Jun. 27

EOSE

Eos Energy Enterprises To Offer $175M Convertible Senior Notes Due 2030 In A Private Offering

Eos Energy Enterprises Announces $75M Common Stock Offering

Comments

SPDR FactSet Innovative Technology ETF

Actualités

Dernières nouvelles pour SPDR FactSet Innovative Technology ETF (ARCA:XITK)

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL